Secondary Databased Post-marketing Surveillance Study of BNT162b2

Pfizer

Status: Completed

Conditions: COVID-19; SARS-CoV-2

Treatments: Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1); Biological: Tozinameran (BNT162b2); Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

Study type: Observational

Funder types: Industry

Identifiers

NCT06743334

C4591056

Details and patient eligibility

About

This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.

Full description

This study is a retrospective, non-interventional, observational study using Korean Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) database that includes COVID-19 vaccination/infection and claims data in Korean population. For the primary objective, cohort and self-controlled design will be used for measure of occurrence and measure of association, respectively. For the secondary objective, cohort design will be used for measure of occurrence.

Primary objective:

• To describe the frequency and estimate the incidence ratio of adverse events of special interest (AESIs) following exposure to Comirnaty Injection among individuals aged 6 months or older in the Republic of Korea
• To evaluate the relative risk of AESIs following exposure to Comirnaty Injection among individuals aged 6 months or older in the Republic of Korea, using a self-controlled case series (SCCS) design

Secondary objective:

• To describe the frequency and estimate the incidence ratio of severe COVID-19 outcomes (COVID-19 hospital admission, COVID-19 intensive care unit [ICU] admission, and COVID-19 death).

Enrollment: 1 patient

Sex: All

Ages: 6+ months old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

1. Primary Objectives 1-1. Measure of Occurrence Inclusion Criteria For the measure of occurrence, analytical populations will include following individuals,

   • Who meet the predefined criteria for each study population.
   • With enrollment in the national insurance during the observation period, as well as during the clean window prior to the start of the observation period.

   Exclusion Criteria For the measure of occurrence, analytical populations will exclude following individuals,

   • With diagnosis of AESI during the AESI-specific clean window; or
   • With diagnosis of AESI between first dose and second/third dose of primary series when analyzing for the second/third dose.

   1-2. Measure of Association Inclusion Criteria For the measure of association, analytical populations will include following individuals,

   • Who meet the predefined criteria for each study population.
   • With enrollment in the national insurance during the observation period, as well as during the clean window prior to the start of the observation period; and
   • Who had incident AESI during the observation period. Exclusion Criteria For the measure of association, analytical populations will exclude following individuals,
   • Who do not have both risk and control window time. If an individual disenrolls, dies, or reaches the end of the study period during the risk window prior to accumulating any control window time, he/she will be excluded; or
   • With a diagnosis of AESI during the AESI-specific clean window.

2. Secondary Objective Inclusion Criteria For the secondary objective, the study populations will include following individuals,

   • Who meet the predefined criteria for each study population. Exclusion Criteria
   • None

Trial design

1 participants in 6 patient groups

All primary series recipients using monovalent vaccine

Description:

All individuals who received first dose with monovalent vaccine as primary series (6 months or older).

Treatment:

Biological: Tozinameran (BNT162b2)

First booster recipients with monovalent vaccine

Description:

All individuals who received first booster recipients with monovalent vaccine (5 years of age or older).

Treatment:

Biological: Tozinameran (BNT162b2)

Second booster recipients with monovalent vaccine

Description:

All individuals who received second booster recipients with monovalent vaccine (5 years of age or older).

Treatment:

Biological: Tozinameran (BNT162b2)

All booster recipients using bivalent vaccine

Description:

All individuals who received booster recipients using bivalent vaccine (12 years of age or older).

Treatment:

Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)

Single-dose primary series recipients with bivalent vaccine

Description:

All individuals who received single-dose primary series recipients with bivalent vaccine (12 years of age or older).

Treatment:

Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)

Primary series recipients with first dose of monovalent vaccine and second dose of bivalent vaccine

Description:

All individuals who received primary series recipients with first dose of monovalent vaccine and second dose of bivalent vaccine (12 years of age or older).

Treatment:

Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)